2022 Fiscal Year Research-status Report
肺癌の免疫治療における腫瘍免疫機能とPET/MRIを用いた画像情報の統合解析
| Project/Area Number |
22K07688
|
|---|
| Research Institution | University of Fukui |
|---|
Principal Investigator |
梅田 幸寛 福井大学, 学術研究院医学系部門(附属病院部), 講師 (80401975)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
石塚 全 福井大学, 学術研究院医学系部門, 教授 (50302477)
岡沢 秀彦 福井大学, 高エネルギー医学研究センター, 教授 (50360813)
|
|---|
| Project Period (FY) |
2022-04-01 – 2026-03-31
|
| Keywords | 免疫チェックポイント阻害剤 / 肺癌 / FLT-PET |
|---|
| Outline of Annual Research Achievements |
【Methods】We evaluated the peripheral blood neutrophil-lymphocyte ratio and each blood cell component, and FLT accumulation in secondary lymphoid tissues such as spleen and hematopoietic tissues such as bone marrow, before and after ICI treatment , to determine their relationship to the therapeutic effect of ICI.
【Results】The median age was 70.4 years, 23 (92%) were male. The histologic types were adenocarcinoma, squamous cell carcinoma, and others in nine (36%), 11 (44%), and four (16%) patients, respectively. Confirmed responses were CR, PR, SD, and PD in one (4%), seven (28%), eight (32%), and nine (36%) patients, respectively.The median changes of SUVs between baseline and two and six weeks after PD-1 inhibitor treatment for the spleen (ΔSUVmean0-2 and ΔSUVmean0-6) was 5.44% and -4.72%, respectively. These values did not differ significantly between the non-PD and PD groups (ΔSUVmean0-2 7.57 vs. -3.61, P = 0.60; ΔSUVmean0-6 -5.28 vs. 3.44, P = 0.69). The changes in any 18F-FLT PET parameters (ΔSUVmax0-2, ΔSUVmean0-2, ΔPPV/BSA0-2, and ΔTVP/BSA0-2) of any thoracic vertebrae (Th4, 8, and 12) between baseline and two weeks later were not significantly different between the non-PD and PD groups, although the 18F-FLT accumulation tended to decrease in the non-PD group and increase in the PD group two weeks after treatment initiation. All parameters of change of 18F-FLT accumulation in the thoracic vertebrae between baseline and 6 weeks after treatment initiation, except ΔSUVmean0-6 in Th4, were significantly lower in the non-PD group than in the PD group.
|
| Current Status of Research Progress |
Current Status of Research Progress
3: Progress in research has been slightly delayed.
Reason
共同研究者が異動となり、本学への帰学、研究できなくなったため進捗に遅れが出ている。
|
| Strategy for Future Research Activity |
今後フローサイトメトリーを用いた検討を行い、末梢血単核球の増殖とFLT集積の関りを検討する。
|
| Causes of Carryover |
計画の進捗にやや遅れが出ており次年度使用が生じた。令和５年度にフローサイトメトリー法による検討を追加するため、抗体などの試薬の購入に充てる予定である。
|
